Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

88.36 -5.94 (-6.30%)
Streaming Delayed Price Updated: 9:34 AM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Kymera Therapeutics to Participate in Upcoming June Investor Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
News headline image
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Growth Stocks That Could Double Your Money in 2023 ↗
For investors that really want to roll the dice, these are the enticing growth stocks that could double your money. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023 ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Buy for 100% Returns ↗
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
News headline image
Join These Motley Fool Investors for "The Market Cap Game Show" ↗
Multiplying the number of shares by the share price is just step one. 
Via The Motley Fool
News headline image
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
News headline image
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
X-Chem and Kymera Expand Existing Partnership
From X-Chem
Via Business Wire
News headline image
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Perfect Presents to Gift Your 2023 Stock Portfolio ↗
As we leave 2022 behind, these hot stocks to buy have significant potential and serious catalysts as we move into New Year 2023. 
Via InvestorPlace
News headline image
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
News headline image
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners ↗
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
News headline image
Dear DS Stock Fans, Mark Your Calendars for Dec. 23 ↗
Drive Shack (DS) stock is falling hard on Wednesday after the company warned investors of it delisting shares this month. 
Via InvestorPlace
News headline image
Why Is SOFI Stock Up 7% Today? ↗
SoFi Technologies (SOFI) stock is climbing higher on Wednesday after the company's CEO bought over 1 million more shares. 
Via InvestorPlace
News headline image
Dear CRKN Stock Fans, Mark Your Calendars for Dec. 22 ↗
Crown Electrokinetics (CRKN) stock is on the move Wednesday as investors prepare for the company's upcoming shareholder meeting. 
Via InvestorPlace
News headline image
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today? ↗
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.